AKTX Stock Summary and Trading Ideas (Akari Therapeutics PLC - American Depositary Shares | NASDAQ:AKTX)

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.

Akari Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AKTX.

As of September 25, 2023, AKTX stock price climbed to $3.85 with 39,472 million shares trading.

AKTX has a beta of 0.54, meaning it tends to be less sensitive to market movements. AKTX has a correlation of 0.01 to the broad based SPY ETF.

AKTX has a market cap of $19.46 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, AKTX stock traded as high as $84.20 and as low as $2.81.

AKTX stock has underperformed the market in the last year with a return of -67.9%, while SPY returned +17.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in AKTX shares. However, AKTX has outperformed the market in the last 3 month and 2 week periods, returning +16.7% and +2.9%, while SPY returned -0.6% and -2.6%, respectively. This indicates AKTX has been having a stronger performance recently.

AKTX support price is $3.32 and resistance is $3.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKTX stock will trade within this expected range on the day.